Pfizer's blood cancer treatment achieved its primary endpoint in a late-stage clinical trial

Glonghui, April 29 — Pfizer announced on Wednesday that its drug Elrexfio achieved its primary endpoint in a late-stage clinical trial involving blood cancer patients who had previously received at least one line of therapy. Elrexfio has already received accelerated approval from the US Food and Drug Administration (FDA) for the treatment of multiple myeloma patients who have undergone at least four prior lines of therapy.